DAREONTM-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results. Comprehensive longitudinal immune cell monitoring in ...
In a new draft guidance issued on January 14, 2026, the FDA discussed the use of a modern statistical methodology in clinical trials designed to ...
Subgroup analysis in clinical trials constitutes a vital methodological tool to uncover differential treatment effects within specified categories of patients. This approach enables researchers to ...
1don MSN
Synthetic protein potentially improves outcomes for select intracerebral hemorrhage patients
Results from the largest-ever clinical trial of its kind found administering a synthetic protein can reduce bleeding and improve outcomes for certain patients at the highest risk of continued bleeding ...
Germline determinants of pneumonitis in patients with cancer treated with antibody drug conjugates. Impact of health literacy in cancer outpatients receiving oral anticancer drugs and followed by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results